BNC Korea Co, Ltd
256840 | KO
Overview
Corporate Details
- ISIN(s):
- KR7256840000
- LEI:
- Country:
- South Korea
- Address:
- 대구광역시 달서구 성서공단로11길 62 대구테크노파크 벤처공장 1호관 405호(사무실),502호, 503호, 206호, 대구광역시
- Website:
- http://www.bnckorea.co.kr
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-29 00:00 |
Legal Proceedings Report
기타경영사항(자율공시) (의약품 회수·폐기 및 잠정 제조중지 등 명령 취소 소송 1심 판결)
|
Korean | 10.7 KB | ||
| 2025-08-26 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (CL-N, N 중국 국가약품감독관리국(NMPA) 품목허가 획득)
|
Korean | 12.6 KB | ||
| 2025-08-14 00:00 |
Annual Report
[기재정정]사업보고서 (2024.12)
|
Korean | 2.1 MB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 1.6 MB | ||
| 2025-07-21 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (Cutegel 중국 국가약품감독관리국(NMPA) 품목허가 획득)
|
Korean | 8.4 KB | ||
| 2025-07-08 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 107.0 KB | ||
| 2025-05-30 00:00 |
Regulatory Filings
기타경영사항(자율공시)
|
Korean | 6.4 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.5 MB | ||
| 2025-04-29 00:00 |
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
|
Korean | 16.5 KB | ||
| 2025-04-08 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 107.2 KB | ||
| 2025-03-31 00:00 |
AGM Information
정기주주총회결과
|
Korean | 19.9 KB | ||
| 2025-03-21 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 25.3 KB | ||
| 2025-03-21 00:00 |
Annual Report
사업보고서 (2024.12)
|
Korean | 2.1 MB | ||
| 2025-03-12 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 195.0 KB | ||
| 2025-03-12 00:00 |
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
|
Korean | 195.4 KB |
Automate Your Workflow. Get a real-time feed of all BNC Korea Co, Ltd filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for BNC Korea Co, Ltd
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BNC Korea Co, Ltd via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Commercial-stage biopharma developing immuno-oncology therapies for hard-to-treat cancers.
United States of America
CHRS
United States of America
CHRS
Develops and commercializes abuse-deterrent medications for responsible chronic pain management.
United States of America
COLL
United States of America
COLL
Develops rhCollagen for 3D bioprinting of tissues for regenerative & aesthetic medicine.
United States of America
CLGN
United States of America
CLGN
Developing psilocybin therapies for severe mental health challenges like TRD and PTSD.
United States of America
CMPS
United States of America
CMPS
A clinical-stage oncology firm developing antibody therapies that engage the immune system.
United States of America
CMPX
United States of America
CMPX
Develops immune modulators for T cell-driven inflammatory diseases like asthma and COPD.
United States of America
CNTB
United States of America
CNTB
Clinical-stage biopharma developing T cell engaging bispecific antibodies for solid tumors.
United States of America
CNTX
United States of America
CNTX
Develops oral small molecule therapies for neurological, inflammatory, and fibrotic diseases.
United States of America
CTNM
United States of America
CTNM
Clinical-stage oncology company developing targeted therapies like ADCs for cancer and obesity.
United States of America
CRBP
United States of America
CRBP
Develops and commercializes cortisol-modulating drugs for severe disorders like Cushing's syndrome.
United States of America
CORT
United States of America
CORT